Abstract:The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise globally. Liver transplant (LT) recipients continue to be older and have inherently more comorbidities. Among these, cardiac disease is one of the three main causes of morbidity and mortality after LT. Several reasons exist including the high prevalence of associated risk factors, which can also be attributed to the rise in the proportion of patients undergoing LT for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, as people age, the prevalence of now treatable cardiac conditions, including coronary artery disease (CAD), cardiomyopathies, significant valvular heart disease, pulmonary hypertension, and arrhythmias rises, making the need to treat these conditions critical to optimize outcomes. There is an emerging body of literature regarding CAD screening in patients with ESLD, however, there is a paucity of strong evidence to support the guidance regarding the management of cardiac conditions in the pre-LT and perioperative settings. This has resulted in significant variations in assessment strategies and clinical management of cardiac disease in LT candidates between transplant centres, which impacts LT candidacy based on a transplant centre's risk tolerance and comfort level for caring for patients with concomitant cardiac disease. Performing a comprehensive assessment and understanding the potential approaches to the management of ESLD patients with cardiac conditions may increase the acceptance of patients, who appear too complex, but rather require extra evaluation and may be reasonable candidates for LT. The unique physiology of ESLD can profoundly influence preoperative assessment, perioperative management, and outcomes associated with underlying cardiac pathology, and requires a thoughtful multidisciplinary approach. The strategies proposed in this manuscript attempt to review the latest expert experience and opinions and provide guidance to practicing clinicians who assess and treat patients being considered for LT. These topics also highlight the gaps that exist in the comprehensive care of LT patients and the need for future investigations in this field. Liver transplant candidates require a detailed cardiovascular assessment, involving a multidisciplinary approach, which incorporates evaluation of traditional and ESLD factors as well as evaluation for cardiac conditions including coronary artery disease, cardiomyopathies, and rhythm disturbances. Liver disease induces systemic hemodynamic changes including portal hypertension, increased cardiac output, and vascular resistance alterations, predisposing candidates to cardiovascular complications. Thorough cardiovascular evaluation may involve non-invasive tests (electrocardiography, echocardiography, cardiac biomarkers, coronary artery calcium score, stress testing) and invasive assessments (coronary angiography) to stratify risk and guide management decisions. Optimal management should involve lifestyle modifications, pharmacotherapy, revascularization for high-risk patients after discussion with a heart team, review of the immunosuppression regimen, and preoperative optimization. Successful cardiovascular management in liver transplant candidates improves perioperative outcomes and reduces postoperative complications. CNI, calcineurin inhibitor; CSA, cyclosporine; ECG, electrocardiogram; ESLD, end-stage liver disease; MELD, model for end-stage liver disease; MASH, metabolic dysfunction-associated steatohepatitis; Tac, tacrolimus.

Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria

The clinical relevance of the new criteria for cirrhotic cardiomyopathy and future directions

P- 35 COMPLICATIONS ASSOCIATED TO THE LIVER TRANSPLANTATION IN PATIENTS WITH CIRRHOTIC CARDIOMYOPATHY

Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according to the proposed new classification

Cardiac evaluation of the liver transplant candidate

Modification of Cardiovascular Risk Factors and the Evolution of The Cardiovascular Phenotype of Liver Transplant Recipients in the Long -Term Postoperative Period

Diagnosis and Management of Cirrhotic Cardiomyopathy

The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria

Cirrhotic cardiomyopathy: Implications for liver transplantation

Cardiovascular disease assessment and management in liver transplantation

Cardiac dysfunction in patients with cirrhosis and acute decompensation

Pretransplant echocardiographic parameters as markers of posttransplant outcomes in liver transplant recipients

Multiparametric Cardiac Magnetic Resonance Imaging Detects Altered Myocardial Tissue and Function in Heart Transplantation Recipients Monitored for Cardiac Allograft Vasculopathy

Impact of pre-transplant cardiac risk factor burden on post-transplant events in liver transplant recipients

Prognostic Value of Mitral Annular Calcification in Liver Transplant Patients: Implication in Posttransplant Outcomes

Systolic and diastolic dysfunction in advanced liver disease: does cirrhotic cardiomyopathy really exist?

Pretransplant Renal Function Evaluated by Serum Cystatin C Was Associated with Mortality after Liver Transplantation: a Single-Center Experience

Impact of left ventricular diastolic dysfunction on liver transplantation outcomes based on the latest American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations

Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?

CACS, CCTA and mCAD‐LT score in the pre‐transplant assessment of coronary artery disease and the prediction of post‐transplant cardiovascular events

Computed tomography pericoronary adipose tissue density predicts coronary allograft vasculopathy and adverse clinical outcomes after cardiac transplantation